Conference Presentation

Mighty Therapeutics details FDA-mandated Phase 4 trial confirming elamipretide in Barth syndrome

The July 22 conference presentation covers a 48-patient confirmatory trial required after FORZINITY's accelerated approval, not a new efficacy readout.

By AppliedXLJuly 14, 2026Trial NCT07531251

Executive Summary

Mighty Therapeutics will use a Barth Syndrome Foundation conference presentation to detail the design and early progress of the confirmatory trial that its accelerated-approval drug depends on.
The trial exists to convert a surrogate-endpoint accelerated approval into full approval, so its outcome carries direct regulatory consequence for the only approved therapy in this ultra-rare disease.
The study has just begun enrolling and dosing patients, with completion years away, so the conference update is a milestone in a long confirmatory process rather than a clinical result.
The therapy faces essentially no direct competitor sharing its mechanism in this indication, making its own trial the field's benchmark rather than one entry in a crowded race.

The presentation

Mighty Therapeutics is scheduled to give an overview of the 4TAZPower study and its progress on FDA-required post-marketing commitments at the Barth Syndrome Foundation conference in Bonita Springs, Florida, running July 19-26, 2026. The trial is registered as NCT07531251, a Phase 4, randomized, double-blind, placebo-controlled study of once-daily subcutaneous elamipretide in patients at least 5 years old with genetically confirmed Barth syndrome. Enrollment is targeted at 48 patients across the United States, United Kingdom, and Canada, with a primary completion date of September 30, 2029. Mighty+1

Probability of Success

Endpoint Met57%

Completes90%

Clinical Significance9%

Regulatory34%

Why the trial exists

FORZINITY (elamipretide) received accelerated approval from the FDA in September 2025 for Barth syndrome patients weighing at least 30kg, based on improvement in knee extensor muscle strength, an intermediate clinical endpoint (a marker used as a stand-in for direct clinical benefit). Accelerated approval carries a mandatory confirmatory trial obligation, and 4TAZPower is that trial, designed to confirm clinical benefit and expand safety data over a 72-week treatment period. Mighty Therapeutics chief executive Reenie McCarthy called dosing of the first patient "a key step toward meeting our post-marketing commitments to the US FDA". Mighty

Where the trial stands

The study moved from Not yet recruiting to Recruiting on July 13, 2026, following a first-patient-dosed announcement on July 8, 2026, with a trial start date of July 2, 2026. Enrollment held at its original target of 48 with no change in size, consistent with a study still in its early recruitment phase. The registry shows no protocol amendments to the primary completion date or endpoints since the trial's initial posting in April 2026. NCT07531251+1

The competitive frame

Elamipretide's only prior trial in this indication, NCT03098797, a completed 12-patient Phase 2/3 study, is the sole direct precedent sharing its Cardiolipin-stabilizing mechanism and Barth syndrome population. No other industry sponsor is running a Cardiolipin-targeted trial in Barth syndrome, and Barth syndrome sits in a target-and-indication pairing with just three registered trials total, all from Stealth BioTherapeutics. FORZINITY remains, per the company, "the only therapy currently approved for this ultra-rare, life-threatening mitochondrial disease". NCT07531251+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.